What is AtriCure?
Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in the development of innovative surgical and non-surgical solutions for cardiac arrhythmias. The company specializes in the design and manufacture of devices that enable surgeons to perform complex procedures with greater precision and efficacy. By focusing on the underlying causes of Afib, AtriCure has carved out a significant niche in the cardiovascular market, providing essential tools that improve patient outcomes and reduce the long-term burden of chronic heart conditions. Its market position is defined by a rigorous commitment to clinical research and technological advancement, ensuring that its product suite remains at the forefront of electrophysiology and cardiac surgery.
How much funding has AtriCure raised?
AtriCure has raised a total of $70.8M across 2 funding rounds:
Other Financing Round
$21M
Stock Offering
$49.8M
Other Financing Round (2002): $21M with participation from Partisan Management Group, Charter Venture Group, Foundation Medical Partners, Camden Partners, U.S. Venture Partners, and New England Partners
Stock Issuance/Offering (2005): $49.8M led by Undisclosed
Key Investors in AtriCure
U.S. Venture Partners
A prominent Silicon Valley venture capital firm specializing in early-stage investments across cybersecurity, enterprise software, and healthcare sectors.
Camden Partners
A growth equity firm with over 25 years of experience, focusing on lower middle market companies within software and technology-enabled business services.
Foundation Medical Partners
An investment entity operating within the hospitals and physicians clinics industry, providing strategic support to medical service providers.
What's next for AtriCure?
Looking ahead, the infusion of capital positions AtriCure to accelerate its research and development pipeline, potentially introducing next-generation ablation technologies to the market. The company is expected to leverage this financial stability to enhance its commercial infrastructure, focusing on broader physician adoption and international market penetration. As the healthcare industry continues to prioritize minimally invasive procedures, AtriCure is well-positioned to capitalize on these trends, driving long-term value for stakeholders while maintaining its focus on improving the standard of care for patients suffering from complex cardiac rhythm disorders.
See full AtriCure company page
